An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 15 Jun 2018 Status changed from recruiting to discontinued.
- 30 Oct 2012 Planned End Date changed from 1 May 2013 to 1 May 2015 as reported by ClinicalTrials.gov.
- 07 Dec 2011 New trial record